Harman Patil (Editor)

CX 516

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Biological half-life
  
45 minutes

PubChem CID
  
148184

ChemSpider
  
130635

Molar mass
  
241.289 g/mol

CAS Number
  
154235-83-3

IUPHAR/BPS
  
4165

UNII
  
Z5QU38B4V9

CX-516

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and is being developed by a collaboration of Cortex and Shire and Servier. It was researched as a treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.

References

CX-516 Wikipedia


Similar Topics